Dec. 11, 2002 — "Developing new and better therapies for osteoporosis and other bone diseases, Velcura Therapeutics, Inc. is interested in strategic partnerships to speed this process and in translating our scientific research from the laboratory bench to the bedside," said Dr. Michael W. Long, scientific founder and CEO of the biotechnology company that was honored at the Dec. 9 Michigan Investment and Commercialization Success Celebration.

Dec. 11, 2002 — Missed this one Monday night after attending it last year, but the Michigan Economic Development Corp. recognized the growth and development of 12 companies, three individuals and two entrepreneurial support groups at the third annual Michigan Investment and Commercialization Success Celebration, held at the Michigan Capitol Rotunda. Winners in advanced manufacturing were Ardesta L.L.C. of Ann Arbor; KTM Industries Inc. of Lansing; Mag Research and Development Co. of Pleasant Ridge; and Quantum Signal L.L.C. of Ann Arbor. Winning in the IT category were Arbortext Inc. of Ann Arbor and Clarity L.L.C. of Troy. The life sciences category was the biggest group with six winners: Ash Stevens Inc. of Detroit; AvTech Laboratories Inc. of Kalamazoo; Neogen Corp. of Lansing; Nephros Therapeutics Inc. of Ann Arbor; NephRx Corp. of Portage; and Velcura Therapeutics Inc. of Ann Arbor. Investors honored were Hal Davis of Blue Gull Network, Dexter; Frank Hennessey of Hennessey Capital, Taylor; and TGap Ventures of Kalamazoo. Two additional awards were given to honor the support of Michigan's entrepreneurial community. Those awards went to David Parsigian of Miller Canfield Paddock & Stone P.L.C.'s Ann Arbor office, and the Detroit office of business consultants McKinsey & Co.

Dec. 10, 2002 — Lansing, Mich., Dec. 10, 2002 – "Developing new and better therapies for osteoporosis and other bone diseases, Velcura Therapeutics, Inc. is interested in strategic partnerships to speed this process and bring the benefits in translating our scientific research from the laboratory bench to the bedside," said Dr. Michael W. Long, scientific founder and CEO of the biotechnology company that was honored at the Dec. 9 Michigan Investment and Commercialization Success Celebration.

Dec. 5, 2002 — Wednesday night, I got a look at some fascinating medical technology from an Ann Arbor biotech startup, Velcura Therapeutics Inc. (Have I mentioned lately how much fun my job is?) Mike Long, who may be the world's most down-to-earth genius-Ph.D.-medical-researcher kind of guy, is opening the doors of his company, which has the modest goal of curing osteoporosis and other dread bone diseases. Long's team at the University of Michigan was the first on the planet to grow human bone cells outside the body.

Nov. 15, 2002 — ANN ARBOR, MICH., Nov. 15, 2002 – Dr. Michael W. Long, the scientific founder, president and chief executive officer of Velcura Therapeutics™, Inc., recently announced five staff additions at its new laboratory in Ann Arbor, Mich. The biotechnology company, which earlier this year received Michigan Life Sciences Corridor (MLSC) funding, recently was recognized by Chicago technology business magazine I-Street as being among the Midwest's top 50 emerging tech companies.